Safety Petition Against Baxter’s Immune Globulin HyQvia Could Limit Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Last-minute petitions traditionally target ANDAs, but this submission raises concerns about a BLA for a product trying to stand out in the relatively undifferentiated immune globulin market.
You may also be interested in...
Subcutaneous Partnerships Are Stepping Stones: Halozyme Touts Its Insulin Product
Despite multiple partnerships around a technology platform that can ease administration of existing drugs, Halozyme says its future prospects revolve more around a significant opportunity in insulin-pump products.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.